They can induce vomiting and nausea for some patients
Temporal trends revealed that discussions of adverse events increased significantly after notable events, including government approvals, viral media coverage, celebrity endorsements, and the expansion of Medicare coverage for weight loss medications
Short-term ibuprofen use (35 days at standard doses) is typically considered acceptable for most patients, but chronic NSAID use alongside GLP-1 therapy warrants closer monitoring
They are considered for: Patients with type 2 diabetes: Individuals whose blood sugar remains high despite using first-line diabetic medications like metformin may benefit from adding a GLP-1 agonist
These findings suggest that semaglutide and tirzepatide may confer important neuroprotective and cerebrovascular advantages beyond their established effects on glycaemic control and cardiovascular risk reduction
Drug interactions may alter insulin needs